Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day.…

Is Eli Lilly Stock a Buy Right Now?

…

Eli Lilly – Foundayo vor EU-Zulassung: Neue Chancen im weltweiten 114-Mrd.-USD-Abnehmboom

Die EMA empfiehlt Foundayo gegen Adipositas und Typ-2-Diabetes. Ein EU-Start ist noch 2026 möglich. Retatrutide erreicht bis zu 28,3…

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lillys Next Leg Higher

Eli Lillys greatest strength isnt Zepbound. It is the companys drug discovery engine.…

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A new government-funded study found that GLP-1 drugs slow the aging process in mice.…

Eli Lilly – Warum ich nach dem Ausbruchsversuch weiter Lilly statt Novo Nordisk bevorzuge

Die Rotation aus Technologieaktien in den Gesundheitssektor macht Eli Lilly (LLY) erneut interessant. Charttechnisch zeigt sich Lilly als klarer Leader-Stock…

Eli Lilly won the first round of the weight-loss boom. Who wins next?

Eli Lilly dominated the first wave of GLP-1s. Now new treatments and shifting consumer spending are creating opportunities beyond the…

Eli Lilly Reports Earnings on Oct. 29. Heres Why the Retatrutide Story Matters More Than the Quarter.

Eli Lillys next big growth driver could be bigger than Zepbound.…

Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.

Lillys recent retreat isnt a sign of a broken investment thesis.…

Better Pharma ETF: iShares IHE vs. State Street XPH

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower…

Eli Lilly-backed TRex Bio closes day flat after IPO

…

Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell

Eli Lillys GLP-1 momentum, new drugs and M&A deals support growth, while pricing pressure and competition pose headwinds.…

Eli Lillys Obesity Business Could Become a Much Bigger Healthcare Platform

…

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lillys revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple,…

FDA Expands Eli Lillys Blood Cancer Drug Label in First-Line Setting

LLYs Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.…

Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study

One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo.…

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity…

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

JNJ trades at a 28% discount on valuation while LLYs cardiometabolic drugs drive 82% of revenue, each bet carries distinct…

Could Eli Lillys Newest Weight Loss Strategy Pay Off for Decades?

The company is constantly thinking big.…

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide…

Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading…

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Heres How the News Could Shake Up the Obesity Drug Market.

Phase three trials on Eli Lillys new weight loss drug, TRIUMPH-2, showed strong results.…

Eli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Eli Lilly Just Announced Game-Changing News

Something new is happening in the weight loss drug market.…

Here are the 4 big things were watching in the stock market in the week ahead

Both sides of the Feds dual mandate are in focus. Plus, Micron reports and Eli Lilly delivers updates on its…

Heres Where Wall Street Analysts See Eli Lillys Share Price Going

Eli Lillys share price climb has decelerated in 2026.…

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will…

Eli Lillys Olumiant receives expanded alopecia indication for children 12 and up

…

LLYs Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D

Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily…

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position…

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly…

Medicare just handed Eli Lilly a massive weight-loss win

As Medicare Bridge participation surges, Novo Nordisks share of those new patients is drawing attention.…

What Eli Lilly’s psychedelic investment could mean for the emerging field

The move may be a sign that Big Pharma companies are becoming more comfortable with the once-stigmatized field.…

Novos CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study

NVOs CagriSema delivers greater weight loss than Eli Lillys tirzepatide in T2D and 21% weight loss in obesity, strengthening its…

Vorsprung im Milliardenmarkt der Abnehmpillen! Eli Lilly hält Rivalen Novo Nordisk auf Distanz!

Marktdominanz bei Senioren: Eli Lilly gewinnt 70 % der rund 700.000 Medicare-Patienten, die seit Juli 2026 neu mit GLP-1-Präparaten…

Eli Lilly CEO offers investors 3 more reasons to stick with the stock

Encouraging updates from Eli Lilly CEO Dave Ricks strengthen the bull case for the stock.…

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Theyre the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched…

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in…

The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect

Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points…

CEO Chat with Dr. Christopher Burns, Chief Executive Officer and Managing Director of Amplia Therapeutics – OTC Markets Life Sciences Virtual Investor Forum

OTCQB: INNMF | ASX: ATXGreg Young: Hello, and welcome to the Life Science Investor Forum. On behalf of OTC Markets…

dpa-AFX ProFeed